Bayer: Dynamic growth – progress in innovation
01 March 2022, Leverkusen: The Bayer Group had a successful year in 2021, both operationally and strategically. “We posted substantial growth,
Read MoreFind the latest news, research, product launches, financial results, investments, partnerships, regulatory developments, and business updates from Bayer. Stay informed on Crop Science, pharmaceuticals, consumer health, crop protection, seeds, biologicals, digital agriculture, healthcare, sustainability, and global business developments.
Bayer AG is a global life science company headquartered in Leverkusen, Germany, operating through three divisions: Crop Science, Pharmaceuticals, and Consumer Health. Its businesses develop products and technologies across agriculture and healthcare, with the company focused on addressing challenges related to food security, climate change, disease prevention, and healthcare access. Bayer’s global portfolio includes seeds, biotechnology traits, crop protection products, digital agriculture solutions, prescription medicines, and consumer healthcare brands.
The Crop Science division is particularly relevant to agriculture, with activities spanning seeds and traits, herbicides, fungicides, insecticides, biologicals, digital farming, and agricultural research. Bayer is advancing a pipeline of new agricultural products while focusing on technologies designed to improve farm productivity, resource efficiency, and resilience. Its current agricultural strategy includes a portfolio of ten planned blockbuster launches.
In India, Bayer has been present for more than 130 years and operates through businesses including Crop Science, Pharmaceuticals and Consumer Health. Bayer CropScience Limited is the group’s listed Indian Crop Science company, with activities covering crop protection, seeds, traits, biologicals and digital farming. The India Crop Science business works with more than 30 million smallholder farmers and focuses on crops including rice, corn, cotton, fruits and vegetables.
Bayer’s global developments in 2026 include Crop Science innovation, financial performance, product pipeline advancement, agricultural technology, sustainability, glyphosate litigation, and strategic investments. The company reported higher Crop Science sales and substantial earnings growth in both the first and second quarters of 2026.
This category features Bayer news, Crop Science, Bayer CropScience India, crop protection, seeds, herbicides, fungicides, insecticides, biologicals, digital agriculture, product launches, R&D, financial results, regulatory developments, sustainability, glyphosate, leadership, investments, partnerships, and global agriculture and healthcare developments.
01 March 2022, Leverkusen: The Bayer Group had a successful year in 2021, both operationally and strategically. “We posted substantial growth,
Read More27 February 2022, Bangladesh: Asian University for Women (AUW) and Bayer AG have announced that Bayer will fund the university education
Read More17 February 2022, New Delhi: Bayer announced today the advancement of key innovation projects that showcase the latest in crop protection,
Read More15 February 2022, Calgary: Sixty-six (66) charities and not-for profit groups across Canada have each received a $2,500 community grant
Read More07 February 2022, Australia: Bayer today announced that it will be launching its industry leading digital farming platform FieldView in
Read More03 February 2022, AU: The Office of the Gene Technology Regulator (OGTR) has begun a public consultation period to assess the
Read More27 January 2022, AU: The promise of a new industry benchmark for grass and broadleaf weed control in wheat and barley
Read More27 January 2022, Germany: Bayer today announced its 2022 cohort of Grants4Ag grant recipients who were chosen to receive awards ranging from
Read More26 January 2022, US: Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, today announced the completion of a Series A
Read MoreTesting4Ag allows scientists to submit novel ideas for the company to test while those researchers and institutions retain all rights
Read More